Test: Difference between revisions
From haematologyetc.co.uk
No edit summary |
No edit summary |
||
| Line 27: | Line 27: | ||
|colspan="1" style = "width: 4%; font-size:90%;"|Mod | |colspan="1" style = "width: 4%; font-size:90%;"|Mod | ||
|colspan="1" style = "font-size:84%;"|Characteristic of CLL, usually less strong than on T cells | |colspan="1" style = "font-size:84%;"|Characteristic of CLL, usually less strong than on T cells | ||
|- | |||
|colspan="1" style = "width: 6%; font-size:90%;" |'''CD11C''' | |||
|colspan="1" style = "width: 6%; background:#00b8e6;"| | |||
|colspan="1" style = "width: 4%; font-size:90%;"|Wk | |||
|colspan="1" style = "font-size:84%;"|Expressed in some cases, but tends to be weak | |||
|- | |||
|colspan="1" style = "width: 7%; font-size:90%;" |'''CD11c''' | |||
|colspan="1" style = "width: 7%; background:#00b8e6; font-size:80%; color:black;" |Wk | |||
|colspan="1" style = "font-size:85%;"| | |||
|- | |- | ||
|colspan="1" style = "width: 6%; font-size:90%;" |'''CD19''' | |colspan="1" style = "width: 6%; font-size:90%;" |'''CD19''' | ||
| Line 53: | Line 62: | ||
|colspan="1" style = "font-size:84%;"|Expression is expected, but characteristically weak | |colspan="1" style = "font-size:84%;"|Expression is expected, but characteristically weak | ||
|- | |- | ||
|colspan="1" style = "width: | |colspan="1" style = "width: 6%; font-size:90%;" |'''CD200''' | ||
|colspan="1" style = "width: | |colspan="1" style = "width: 6%; background:#66e0ff;"| | ||
|colspan="1" style = "width: 4%; font-size:90%;"|Wk | |||
|colspan="1" style = "font-size:84%;"|Characteristically positive in CLL and negative in MCL | |||
|colspan="1" style = "width: | |||
|colspan="1" style = "font-size: | |||
|- | |- | ||
|colspan="1" style = "width: 7%; font-size:90%;" |'''CD11c''' | |colspan="1" style = "width: 7%; font-size:90%;" |'''CD11c''' | ||
Revision as of 19:41, 16 June 2023
Background
Typical CLL can be diagnosed with some confidence using flow cytometry. CLL cells express low levels of B-cell receptor associated molecules (e.g. CD19, CD79B and sIg) together with CD5 and CD23 in typical cases. However, atypical cases are regularly encoutered and can cause diagnosic difficulty.
| Immunophenotype of CLL | |||
|---|---|---|---|
| Major markers useful in CLL diagnosis | |||
| κ/λ | wk | Either weak restricted κ or λ or undetectable expression | |
| FMC7 | wk | May be expressed by atypical cases, generally absent | |
| CD5 | Mod | Characteristic of CLL, usually less strong than on T cells | |
| CD11C | Wk | Expressed in some cases, but tends to be weak | |
| CD11c | Wk | ||
| CD19 | Wk/ mod | Expression is expected, but less strong than normal B cells | |
| CD20 | Wk | Expression is expected, but characteristically weak | |
| CD23 | Wk/ Mod | Characteristic of CLL, although can rarely be weak or absent | |
| CD43 | Wk/ Mod | Similar to CD200, may be helpful in some cases | |
| CD79A | Wk | Expression is expected, but characteristically weak | |
| CD200 | Wk | Characteristically positive in CLL and negative in MCL | |
| CD11c | Wk | Expressed in some cases, but tends to be wk | |
| CD103 | - | Not expressed by CLL, consider HCL if found | |
| CD10 | Wk | Rare in CLL, consider FL if detected | |
Pitfalls and atypical cases